HSBC Holdings
LCTX icon

HSBC Holdings’s Lineage Cell Therapeutics LCTX Stock Holding History

HSBC Holdings’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72,248
Closed -$66K – 2957
2025
Q2 		$66K Buy
72,248
+51,288
+245% +$30.4K ﹤0.01% 2909
2025
Q1 		$9.84K Buy
20,960
+3,572
+21% +$2.1K ﹤0.01% 2985
2024
Q4 		$8.75K Sell
17,388
-300
-2% -$220 ﹤0.01% 3073
2024
Q3 		$16.1K Buy
17,688
+2,696
+18% +$2.5K ﹤0.01% 2955
2024
Q2 		$14.5K Sell
14,992
-226
-1% -$250 ﹤0.01% 2885
2024
Q1 		$22.5K Buy
+15,218
New +$17.3K ﹤0.01% 2987
2017
Q1 		– Sell
-13,670
Closed -$43K – 2370
2016
Q4 		$43K Buy
+13,670
New +$42K ﹤0.01% 2675

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $35.6M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return